News

WALTHAM, Mass.--(BUSINESS WIRE)--Mar. 14, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that three posters highlighting the Company’s expertise in ADCs will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting to be held from April 14-18, 2018 in Chicago.

“ImmunoGen has in-depth expertise in all aspects of ADCs, which has resulted in the most comprehensive toolbox of ADC technologies in the industry,” said Richard Gregory, Ph.D., ImmunoGen’s chief scientific officer. “The data to be presented at AACR further build on our leadership position in the space and demonstrate continued innovation, including further advancements to payloads and targets for anti-tumor activity, as well as insights into factors that determine the clinical efficacy of ADCs.”

Details of ImmunoGen’s poster presentations are as follows:

Title: “A new class of DNA alkylating indolino-benzodiazepine agents (BIAs) linked with a DNA binding moiety for use with antibody-drug conjugates (ADCs)” (abstract #747)
Date:April 15, 2018
Time: 1:00 – 5:00pm CT

• A new class of DNA alkylating effector molecules for use in ADC development in which an IGN (indolino-benzodiazepine) monomer subunit is connected to a DNA binding moiety (e.g., Bi-Aryl, or Bis-Aryl) are termed BIAs. BIA ADCs displayed potent, antigen-specific in vitro activity across a panel of FRα-expressing cell lines. In vivo, these ADCs demonstrated potent efficacy in xenograft models at doses well below the maximum tolerated dose.

Title: “Development of an in vivo model system to assess the interplay between the various drivers of antibody drug conjugate (ADC) activity” (abstract #753)
Date:April 15, 2018
Time: 1:00 – 5:00pm CT

• To better understand the variables that impact ADC pharmacokinetics, tolerability, bio-distribution, and efficacy, a novel, cross-reactive model system was created. An anti-murine folate receptor alpha (FRα) antibody was generated that binds to both mouse and human FRα. The model system allows experiments to be designed in a cross-reactive system to examine how modifications to the antibody, linker or cytotoxic payload impact safety, and efficacy.

Title: “Evaluation of endoglin/CD105 as a tumor vasculature target with antibody drug conjugates” (abstract #2900)
Date:April 16, 2018
Time: 1:00 – 5:00pm CT

• Endoglin/CD105 is a well-acknowledged endothelial cell proliferation marker, which is strongly expressed in tumor-associated vasculature. It was evaluated as an oncology target using ADCs of an anti-CD105 antibody with potent anti-microtubule maytansinoids DM1 and DM4, and the highly potent IGN DNA-alkylating payload, DGN549. Endoglin targeted huRH105-DM and huRH105-DGN549 conjugates produced modest anti-tumor activity and therapeutic indices in rat models.

Additional information and full abstracts can be found at www.aacr.org.

About ImmunoGen, Inc.
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. The Company’s lead product candidate, mirvetuximab soravtansine, is in the Phase 3 FORWARD I trial for FRα-positive platinum-resistant ovarian cancer, and is in the Phase 1b/2 FORWARD II trial in combination regimens for earlier-stage disease. ImmunoGen has three additional clinical-stage product candidates, two of which are being developed in collaboration with Jazz Pharmaceuticals. ImmunoGen's ADC technology is also used in Roche's marketed product, Kadcyla^®, and in programs in development by Amgen, Bayer, Biotest, CytomX, Debiopharm, Lilly, Novartis, Sanofi and Takeda. More information about the Company can be found at www.immunogen.com.

Kadcyla^® is a registered trademark of Genentech, a member of the Roche Group.

This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the development of novel anticancer products, including risks related to preclinical and clinical studies, their timings and results. A review of these risks can be found in ImmunoGen's Annual Report on Form 10-K for the year ended December 31, 2017 and other reports filed with the Securities and Exchange Commission.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180314005853/en/

Source: ImmunoGen, Inc.

For Investors
ImmunoGen, Inc.
Sarah Kiely, 781-895-0600
sarah.kiely@immunogen.com
or
For Media
ImmunoGen, Inc.
Courtney O’Konek, 781-895-0600
courtney.okonek@immunogen.com
or
FTI Consulting Inc.
Robert Stanislaro, 212-850-5657
robert.stanislaro@fticonsulting.com